Unicycive Therapeutics Inc.
UNCY | NASDAQ
$4.77
-$0.03 (-0.63%)
At close: Sep 21, 2026, 4:00 PM ET
$4.77
$0 (0.00%)
Pre-market:
Sep 22, 2026, 8:44 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | 675K | 951K | n/a | n/a |
Cost of Revenue | 572K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -572K | n/a | 675K | 951K | n/a | n/a |
Operating Income | -29.52M | -32.12M | -20.77M | -18.05M | -8.98M | -2.02M |
Interest Income | 1.01M | 1.26M | 615K | n/a | n/a | 244K |
Pretax Income | -26.56M | -36.73M | -30.54M | -18.06M | -10.02M | -2.26M |
Net Income | -26.56M | -36.73M | -30.54M | -18.06M | -10.02M | -2.51M |
Selling & General & Admin | 20.4M | 12.1M | 8.55M | 6.57M | 2.9M | 1.01M |
Research & Development | 9.12M | 20.01M | 12.9M | 12.44M | 6.08M | 1.02M |
Other Expenses | -572K | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 28.95M | 32.12M | 21.45M | 19M | 8.98M | 2.02M |
Interest Expense | 71K | 71K | 82K | 6K | 628K | 244K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 29.52M | 32.12M | 21.45M | 19M | 8.98M | 2.02M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 15.89M | 6.7M | 2.45M | 1.51M | 1.5M | 1.52M |
Shares Outstanding (Diluted) | 15.89M | 6.7M | 2.45M | 1.51M | 1.5M | 1.52M |
EPS (Basic) | -1.67 | -5.65 | -12.80 | -11.99 | -6.68 | -1.48 |
EPS (Diluted) | -1.67 | -5.65 | -12.80 | -11.99 | -6.68 | -1.48 |
EBITDA | -25.91M | -36.23M | -30.18M | -17.89M | -9.38M | n/a |
EBIT | -26.48M | -36.66M | -30.46M | -18.05M | -9.39M | -2.02M |
Depreciation & Amortization | 572K | 428K | 284K | 161K | 13K | 2.02M |
Add to Watchlist
Select watchlists to add or remove UNCY